Reading XCUR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track XCUR free→Reading XCUR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track XCUR free→QuarterlyIQ Insights · XCUR
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Director Appointment and Appointment of Chair of the Audit Committee On April 8, 2026, the Board of Directors (the “Board”) of Exicure, Inc. (the “Company”) appointed Yoontae Han to serve as a director of the Company, effective as of April 8, 2026, until a successor has been duly elected and qualified or until his earlier death, resignation or remov…
Other Events. On March 19, 2026, the United States District Court for the Northern District of Illinois (the “Court”) preliminarily approved the settlement (“Settlement”) of stockholder derivative claims brought on behalf of Exicure, Inc. (the “Company” or “Exicure”), as well as potential claims asserted by certain Exicure stockholders, in accordance with that certain Stipulation and Agreement of Settlement dated March 18, 2026. The Settlement is intended to fully and finally resolve the foll…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Resignation of Director from the Board of Directors On March 25, 2026, Sangjin Yeo submitted his resignation from the Board of Directors (the “Board”) and the Audit Committee of the Board of Exicure, Inc. (the “Company”), effective as of March 27, 2026. This resignation did not result from any disagreement regarding any matter related to the operati…
in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set fo…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Executive Management Change On February 11, 2026, the board of directors (the “Board”) of Exicure, Inc. (the “Company”) appointed Jung Soo Kim as the Chief Executive Officer and President of the Company, and also appointed Gyuyeob Lee as the Interim Chief Financial Officer and Secretary of the Company, each effective as of February 11, 2026. These a…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Resignation of Directors to the Board of Directors On February 6, 2026, (i) Andy Yoo, (ii) Seung Ik Baik, and (iii) Aejin Hwang resigned from the Board of Directors (the “Board”) of Exicure, Inc. (the “Company”), effective February 9, 2026. The resignations of these three Board members did not result from any disagreement regarding any matter relate…
Other Events Completion of Milestone 1 On January 16, 2026, Exicure, Inc. (the “Company”) achieved the first contractual milestone under its License and Collaboration Agreement (the “Agreement”) with GPCR Therapeutics Inc. The milestone relates to the completion of the Company’s Phase 2 clinical trial of its novel stem cell mobilizer (NCT05561751), which was achieved through the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026. Under…
in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set fo…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers Election of Directors to the Board of Directors On September 8, 2025, the Board of Directors (the “Board”) of Exicure, Inc. (the “Company”) appointed (i) Sangjn Yeo and (ii) Aejin Hwang to the Board to serve, until a successor has been duly elected and qualified or until an earlier death, resignation or removal. Each of Mr. Yeo and Ms. Hwang will serve as a Class II director for a term expir…
in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set fo…
in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set fo…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers Executive Management Updates As of June 6, 2025, the Board of Directors of the Company approved severance packages and adjustments to the annual base salaries of the Company’s Chief Executive Officer, Andy Yoo, and its Chief Financial Officer, Seung Ik Baik. Mr. Yoo’s salary was increased to $480,000, and Mr. Baik’s salary was increased to $300,000. If the Company terminates employment of Mr…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 21, 2025, Exicure, Inc. (the “Company”) received a delinquency notification letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that due to the delay in filing the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing…
Entry into a Material Definitive Agreement On April 30, 2025, Exicure, Inc. (the “Company”) entered into a convertible bond agreement (the “Convertible Bond Agreement”) with KC Creation Co., Ltd. (“KC Creation”), the Company’s wholly owned South Korean subsidiary. Pursuant to the Convertible Bond Agreement, the Company purchased non-guaranteed private placement convertible bonds (the “Bonds”) of KC Creation for a subscription amount of 4.5 million KRW, or approximately $3.125 million USD. The…
Changes in Registrant's Certifying Accountant Based on information provided by Marcum LLP (“Marcum”), the independent registered public accounting firm of Exicure, Inc. (the “Company”), CBIZ CPAs P.C. (“CBIZ CPAs”) acquired the attest business of Marcum, effective November 1, 2024. Marcum continued to serve as the Company’s independent registered public accounting firm through April 10, 2025. On April 10, 2025, Marcum resigned as the Company’s independent registered public accounting firm, an…
in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set fo…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers Resignation of Jiyoung Hwang On February 28, 2025, Jiyoung Hwang resigned from the Board of Directors (the “Board”) of Exicure, Inc. (the “Company”) for personal reasons, effective immediately as of such date. Her resignation did not result from any disagreement regarding any matter related to the operations, policies or practices of the Company. Resignation of Paul Kang On February 1, 2025,…
Entry Into a Material Definitive Agreement Common Stock Purchase Agreement On February 14, 2024, Exicure, Inc. (the “Company”) entered into a Common Stock Purchase Agreement with Shin Chang Partners and RMS0718 Co., Ltd. (the “Purchasers”), pursuant to which the Company agreed to issue and sell to each of the Purchasers 145,454 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $5.50 per share. Other than in respect of the Common Sto…
Based in part upon the representations of the Purchasers in the Common Stock Purchase Agreement, the offering and sale of the securities will be made in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act. The sale of the securities will not involve a public offering and will be made without general solicitation or general advertising. The Purchasers represented that they are an accredited investor, as such term is defined in Rule 501(a) of Regulation D under the Secur…
Entry Into a Material Definitive Agreement On January 19, 2025, Exicure Inc. (“the Company”) entered into a Share Purchase Agreement with GPCR Therapeutics Inc, a Korean corporation, (“GPCR”) pursuant to which the Company acquired from GPCR all of the issued and outstanding equity securities of GPCR Therapeutics USA Inc., a California corporation (“GPCR USA”). The transactions contemplated under the Share Purchase Agreement closed concurrently with execution. GPCR USA was, until immediately p…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.